Production and characterisation of monoclonal antibodies to human interleukin-12

1997 ◽  
Vol 56 (1-3) ◽  
pp. 280
Author(s):  
R Carter
2001 ◽  
Vol 69 (10) ◽  
pp. 6445-6455 ◽  
Author(s):  
David O. Beenhouwer ◽  
Scott Shapiro ◽  
Marta Feldmesser ◽  
Arturo Casadevall ◽  
Matthew D. Scharff

ABSTRACT Variable-region-identical mouse immunoglobulin G1 (IgG1), IgG2b, and IgG2a monoclonal antibodies to the capsular polysaccharide ofCryptococcus neoformans prolong the lives of mice infected with this fungus, while IgG3 is either not protective or enhances infection. CD4+ T cells are required for IgG1-mediated protection, and CD8+ T cells are required for IgG3-mediated enhancement. Gamma interferon is required for both effects. These findings revealed that T cells and cytokines play a role in the modulation of cryptococcal infection by antibodies and suggested that it was important to more fully define the cytokine requirements of each of the antibody isotypes. We therefore investigated the efficacy of passively administered variable-region-identical IgG1, IgG2a, IgG2b, and IgG3 monoclonal antibodies against intravenous infection withC. neoformans in mice genetically deficient in interleukin-12 (IL-12), IL-6, IL-4, or IL-10, as well as in the parental C57BL/6J strain. The relative inherent susceptibilities of these mouse strains to C. neoformans were as follows: IL-12−/− > IL-6−/− > C57BL/6J ≈ IL-4−/− ≫ IL-10−/−. This is consistent with the notion that a Th1 response is necessary for natural immunity against cryptococcal infection. However, none of the IgG isotypes prolonged survival in IL-12−/−, IL-6−/−, or IL-4−/− mice, and all isotypes significantly enhanced infection in IL-10−/− mice. These results indicate that passive antibody-mediated protection againstC. neoformans requires both Th1- and Th2-associated cytokines and reveal the complexity of the mechanisms through which antibodies modulate infection with this organism.


Hybridoma ◽  
2008 ◽  
Vol 27 (3) ◽  
pp. 141-151 ◽  
Author(s):  
Subhajit Dasgupta ◽  
Mausumi Bandopadhyay ◽  
Kalipada Pahan

1997 ◽  
Vol 56 ◽  
pp. 280
Author(s):  
R.W. Carter ◽  
P.M. Patel ◽  
A.J. Stanley ◽  
E. Ingham ◽  
M. Wadhwa ◽  
...  

Blood ◽  
1999 ◽  
Vol 94 (12) ◽  
pp. 4347-4357 ◽  
Author(s):  
Eric Muraille ◽  
Fabienne Andris ◽  
Bernard Pajak ◽  
K. Martin Wissing ◽  
Thibaut De Smedt ◽  
...  

Abstract Antibodies against CD3ɛ are widely used as immunosuppressive agents. Although it is generally assumed that these reagents exert their immunomodulatory properties by inducing T-cell deletion and/or inactivation, their precise mechanism of action remains to be elucidated. Using a murine model, we demonstrate in this report that administration of anti-CD3ɛ antibodies causes the migration and maturation of dendritic cells (DC) in vivo, as determined by immunohistochemical analysis. This maturation/migration process was followed by selective loss of splenic DC, which resulted in a selective inhibition of antigen-presenting cell (APC) functions in vitro. Spleen cells from anti-CD3ɛ–treated animals were unable to productively stimulate naive alloreactive T cells and Th1-like clones in response to antigen, while retaining the ability to present antigen to a T-cell hybridoma and Th2 clones. Anti-CD3ɛ treatment was found to induce a selective deficiency in the ability of spleen cells to produce bioactive interleukin-12 in response to CD40 stimulation. APC dysfunction was not observed when nonmitogenic forms of anti-CD3ɛ antibodies were used, suggesting that splenic DC loss was a consequence of in vivo T-cell activation. Nonmitogenic anti-CD3ɛ monoclonal antibodies were found to be less immunosuppressive in vivo, raising the possibility that APC dysfunction contributes to anti-CD3ɛ–induced immunomodulation. Collectively, these data suggest a novel mechanism by which mitogenic anti-CD3ɛ antibodies downregulate immune responses.


Blood ◽  
1999 ◽  
Vol 94 (12) ◽  
pp. 4347-4357
Author(s):  
Eric Muraille ◽  
Fabienne Andris ◽  
Bernard Pajak ◽  
K. Martin Wissing ◽  
Thibaut De Smedt ◽  
...  

Antibodies against CD3ɛ are widely used as immunosuppressive agents. Although it is generally assumed that these reagents exert their immunomodulatory properties by inducing T-cell deletion and/or inactivation, their precise mechanism of action remains to be elucidated. Using a murine model, we demonstrate in this report that administration of anti-CD3ɛ antibodies causes the migration and maturation of dendritic cells (DC) in vivo, as determined by immunohistochemical analysis. This maturation/migration process was followed by selective loss of splenic DC, which resulted in a selective inhibition of antigen-presenting cell (APC) functions in vitro. Spleen cells from anti-CD3ɛ–treated animals were unable to productively stimulate naive alloreactive T cells and Th1-like clones in response to antigen, while retaining the ability to present antigen to a T-cell hybridoma and Th2 clones. Anti-CD3ɛ treatment was found to induce a selective deficiency in the ability of spleen cells to produce bioactive interleukin-12 in response to CD40 stimulation. APC dysfunction was not observed when nonmitogenic forms of anti-CD3ɛ antibodies were used, suggesting that splenic DC loss was a consequence of in vivo T-cell activation. Nonmitogenic anti-CD3ɛ monoclonal antibodies were found to be less immunosuppressive in vivo, raising the possibility that APC dysfunction contributes to anti-CD3ɛ–induced immunomodulation. Collectively, these data suggest a novel mechanism by which mitogenic anti-CD3ɛ antibodies downregulate immune responses.


1996 ◽  
Vol 795 (1 Interleukin 1) ◽  
pp. 334-336 ◽  
Author(s):  
F. FAUCHET ◽  
M. JADOUL ◽  
J. D. FRANSSEN ◽  
J. ZHANG ◽  
D. DE GROOTE

Hybridoma ◽  
1997 ◽  
Vol 16 (4) ◽  
pp. 363-369 ◽  
Author(s):  
R.W. CARTER ◽  
P.M. PATEL ◽  
A.J. STANLEY ◽  
E. INGHAM ◽  
M. WADHWA ◽  
...  

2004 ◽  
Vol 110 (1) ◽  
pp. 51-60 ◽  
Author(s):  
Iñigo Tirapu ◽  
Ainhoa Arina ◽  
Guillermo Mazzolini ◽  
Marina Duarte ◽  
Carlos Alfaro ◽  
...  

Author(s):  
James E. Crandall ◽  
Linda C. Hassinger ◽  
Gerald A. Schwarting

Cell surface glycoconjugates are considered to play important roles in cell-cell interactions in the developing central nervous system. We have previously described a group of monoclonal antibodies that recognize defined carbohydrate epitopes and reveal unique temporal and spatial patterns of immunoreactivity in the developing main and accessory olfactory systems in rats. Antibody CC2 reacts with complex α-galactosyl and α-fucosyl glycoproteins and glycolipids. Antibody CC1 reacts with terminal N-acetyl galactosamine residues of globoside-like glycolipids. Antibody 1B2 reacts with β-galactosyl glycolipids and glycoproteins. Our light microscopic data suggest that these antigens may be located on the surfaces of axons of the vomeronasal and olfactory nerves as well as on some of their target neurons in the main and accessory olfactory bulbs.


Sign in / Sign up

Export Citation Format

Share Document